Yi-Long Wu

Trials

Studies that name Yi-Long Wu as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 01:11 UTC. Open this list on ClinicalTrials.gov

• Ph2
  NCT07750704 · Lorlatinib Plus Sacituzumab Tirumotecan With Peripheral ctDNA Guidance as First-Line Therapy for ALK Fusion-Positive NSCLC

  Guangdong Association of Clinical Trials · not yet recruiting · ALK Positive Non-small Cell Lung Cancer · principal investigator
• N/A
  NCT06709274 · Minimal Residual Disease Guiding Adjuvant Therapy in Stage I NSCLC

  Guangdong Association of Clinical Trials · not yet recruiting · Non-Small Cell Lung Cancer · principal investigator
• Ph2
  NCT06574347 · Vebreltinib Plus PLB1004 as the First-line Therapy for Patients With EGFRm+/MET+ Locally Advanced or Metastatic NSCLC.

  Avistone Biotechnology Co., Ltd. · recruiting · Non-Small-Cell Lung Cancer
• Ph2
  NCT06092086 · Lorlatinib as the First-line Treatment in China Advanced ALK+ NSCLC

  Guangdong Association of Clinical Trials · recruiting · ALK Positive Non-small Cell Lung Cancer · principal investigator
• Ph1
  NCT05205109 · A Study to Assess the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of ATG 037 Monotherapy and Combination Therapy With Pembrolizumab in Patients With Advanced Solid Tumors

  Antengene Therapeutics Limited · recruiting · Locally Advanced or Metastatic Solid Tumors · principal investigator
• Ph2
  NCT04252365 · Sintilimab Versus Pembrolizumab for Advanced-stage Non-Small-Cell Lung Cancer

  Guangdong Association of Clinical Trials · unknown · Nsclc · study chair
• N/A
  NCT04007835 · Anlotinib Hydrochloride Combined With EGFR-Tyrosine Kinase Inhibitor (TKI) in Treating Advanced NSCLC Patients With Acquired Resistance to EGFR-TKI

  Guangdong Association of Clinical Trials · unknown · NSCLC · study chair
• N/A
  NCT03605602 · A Real World Study Based on NGS (TRUMPRWS)

  Guangdong Association of Clinical Trials · unknown · Non-Small Cell Carcinoma of Lung, TNM Stage 4 · study chair
• Ph2
  NCT03574402 · Phase II Umbrella Study Directed by Next Generation Sequencing

  Guangdong Association of Clinical Trials · unknown · Carcinoma, Non-Small-Cell Lung · study chair
• Ph2
  NCT02725918 · Pemetrexed vs Pemetrexed Plus Cisplatin in EGFR-mutant NSCLC Patients After First Line EGFR-TKIs Failure

  Guangdong Association of Clinical Trials · unknown · Non-small Cell Lung Cancer
• N/A
  NCT02113852 · Study of Blood, Tumor and Adjacent Normal Tissue Samples From Chinese Smoking Induced Lung Cancer Patients

  Guangdong Association of Clinical Trials · completed · Non Small Cell Lung Cancer · principal investigator
• Ph2
  NCT02095782 · Chemotherapy and Erlotinib for Lung Cancer With Low Abundance Epidermal Growth Factor Receptor Mutation

  Guangdong Association of Clinical Trials · terminated · Non-small-cell Lung Cancer · study chair
• N/A
  NCT02042105 · A Prospective Epidemiologic Study of ALK-Positive NSCLC in China

  Guangdong Association of Clinical Trials · completed · Non-small-cell Lung Cancer · principal investigator
• N/A
  NCT01740804 · Dynamic Circulating Tumor Cell (CTC) Changes During the Chemotherapy in NSCLC

  Guangdong Association of Clinical Trials · completed · Carcinoma, Non-Small-Cell Lung, Cell, Circulating Tumor · principal investigator
• Ph2/Ph3
  NCT01407822 · Erlotinib Versus Gemcitabine/Cisplatin as (Neo)Adjuvant Treatment in Non-small Cell Lung Cancer

  Guangdong Association of Clinical Trials · unknown · Non-small Cell Lung Cancer · principal investigator
• Ph3
  NCT01405079 · Gefitinib Versus Vinorelbine/Platinum as Adjuvant Treatment in Stage II-IIIA(N1-N2) NSCLC With EGFR Mutation

  Guangdong Association of Clinical Trials · unknown · Non-small Cell Lung Cancer · principal investigator
• Ph2/Ph3
  NCT01319669 · Clinical Trial on the Prevention of Thrombocytopenia After First-line Chemotherapy

  Chinese Society of Lung Cancer · terminated · Carcinoma, Non-Small-Cell Lung · principal investigator
• Ph2
  NCT00600587 · Induction Erlotinib Therapy in Stage III A (N2) Non-Small Cell Lung Cancer (NSCLC)

  Guangdong Provincial People's Hospital · completed · Carcinoma, Non-Small-Cell Lung · principal investigator
• Ph3
  NCT00321334 · Survival Study of Docetaxel and Carboplatin as Neo-Adjuvant Vs Adjuvant Chemotherapy in Early Stage NSLC

  Chinese Society of Lung Cancer · completed · Non-small Cell Lung Cancer · principal investigator

Grants

NIH projects from RePORTER, fetched 2026-11-12 01:11 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.

No NIH project could be tied to this name by a shared trial or a matching institution.